AstraZeneca Licenses Dizal’s Zegfrovy for Up to $1.5B
AstraZeneca has entered an exclusive global license agreement with China-based Dizal Pharmaceutical for Zegfrovy (sunvozertinib), an oral, irreversible EGFR inhibitor for non-small cell lung cancer harboring EGFR exon 20 insertion mutations. The agreement carries…
